Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sachiko Takenoshita
Observed names:
Sachiko TAKENOSHITA,
Takenoshita Sachiko
Institution:
SHOWA Medical University
Observed institution:
SHOWA Medical University
ORCID:
0000-0001-7858-3558
Observed ORCID:
0000-0001-7858-3558
OpenAlex ID:
A5072676200
A Study on Pharmacokinetics of Acetylsalicylic Acid Mini-Tablets in Healthy Adult Males—Comparison with the Powder Formulation
2023
·
Noriko Hida
, Taigi Yamazaki
, et al.
·
Pharmaceutics
·
10
PDF
Comparative Analysis of Verapamil Pharmacokinetics: Evaluating the Impact of Simple Suspension and Crushing Administration Methods
2024
·
Sumito Kumagai
, Takehiko Sambe
, et al.
·
Journal of Clinical Medicine
·
8
PDF
Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors
2023
·
Ryotaro Ohkuma
, Sakiko Miura
, et al.
·
Frontiers in Immunology
·
5
PDF
Effect of the Simple Suspension Method and Crushing Method on the Pharmacokinetics of Temocapril Combined with Magnesium Oxide
2021
·
Hanami Machino
, Noriko Hida
, et al.
·
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
·
2
PDF
Abstract CT032: Promotive clinical effects of pembrolizumab with necitumumab in patients having advanced non-small cell lung cancer with PD-L1 expression of 50% or higher in a phase II study (K-TAIL-202)
2024
·
Atsushi Horiike
, Hiroshi Wakui
, et al.
·
Cancer Research
·
1
Clinical Pharmacokinetics of Mianserin Suppositories in Healthy Older Japanese Male Adults: A Pilot Study
2019
·
Daisuke ICHIKURA
, Shuichi NAWATA
, et al.
·
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
·
1
Supplementary Data1 from Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
2026
·
Atsushi Horiike
, Hiroshi Wakui
, et al.
Data from Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
2026
·
Atsushi Horiike
, Hiroshi Wakui
, et al.
Figure S1 from Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
2026
·
Atsushi Horiike
, Hiroshi Wakui
, et al.
Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
2026
·
Atsushi Horiike
, Hiroshi Wakui
, et al.
·
Clinical Cancer Research
Durable efficacy of first-line necitumumab plus pembrolizumab in PD-L1–high advanced NSCLC: Final results of the phase II K-TAIL-202 study.
2026
·
Atsushi Horiike
, Hiroshi Wakui
, et al.
·
Journal of Clinical Oncology
Investigation of the Significance of Pharmacological Training on Human Subjects Using Diuretics in Practical Pharmacology for Medical Students
2019
·
Taigi YAMAZAKI
, Takehiko SAMBE
, et al.
·
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
PDF
Internet Survey of Clinical Trial Information for Patients at University Hospitals in Japan
2019
·
Tetsuya SASAKI
, Takehiko SAMBE
, et al.
·
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
PDF
大学病院における臨床試験(治験)の促進と実地教育の促進 ‐昭和大学 8 附属病院治験ネットワークの構築‐
2017
·
Sambe Takehiko
, Uchikura Takeshi
, et al.
·
臨床薬理
Promotion of Clinical Research Including Clinical Trial and Practical Practice in University Hospital
2017
·
Takehiko SAMBE
, Takeshi UCHIKURA
, et al.
·
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
PDF
Show more works
View as search
Works count:
15
Citation count:
27
H-index:
3
I10-index:
1
Year
Topic
Type